What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “40 ml Cerebrolysin and 60 ml 0.9% NaCl per day for 4 days every month for 1 year”In the company’s words, NCT05755997 on ClinicalTrials.gov
- Tested for
- Cadasil
- Main trialPhase 2
- “The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to Placebo in patients with genetically proven CADASIL. In addition, a traditional approach will be taken based on an evaluation of the separate risk and benefit domains in comparison with placebo.”In the company’s words, NCT05755997 on ClinicalTrials.gov
- Other names
- Renacenz
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 Mar 2026 | CERebrolysin In CADASIL | |
| Phase 4Completed | Oct 2010 | The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke | |
| Phase 4Completed | not given | A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia | |
| Phase 2Terminated | 21 Mar 2022 | IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE | |
| Phase 3/4Under evaluation | not given | Efficacy and safety of Cerebrolysin for neurorecovery after moderate-severe traumatic brain injury | |
| Phase 3Authorised | not given | A confirmatory, randomized, placebo-controlled, double-blind, multicenter trial to assess the efficacy of CEREBROLYSIN in post-acute ischemic stroke recovery (CARS-CT) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026